Red Cell DRM Acquisition Corp.
- Registration2021-03-17 Filed S1
- Withdrawn2022-05-05 Merger Withdrawn
- SPAC Ticker
- Renewable Energy, Energy
Gavin Hood serves as our Chief Executive Officer and as a member of our board of directors . Mr. Hood’s dedication to Red Cell DRM Acquisition Corp. follows more than two decades in highly complex public and private sector leadership roles. From 2012-2020, after more than a decade of public service, Mr. Hood was appointed Chief of Staff and Global Director of Business and Operations at Palantir Technologies (NYSE: PLTR), the world’s leading data analytics company. Working closely with Palantir’s CEO and co-founders, Mr. Hood served in a dynamic leadership role that spanned every aspect of Palantir’s business that included reporting relationships across functions such as sales, recruitment, global operations, legal and media, and directly drove the company’s growth into a global multi-billion-dollar enterprise. Over the course of eight years, Mr. Hood built and oversaw a wide range of the company’s global operations, hired and managed some of the firm’s strongest talent, and led global business development where he launched industry-changing joint ventures, spearheaded expansion into new geographies, and crafted and executed strategies that produced over $1.0 billion in contract value. During his tenure, Mr. Hood also helped navigate transformative policy challenges regarding the role of private industry in national security and developed critical initiatives to address the complexities associated with technology, national security, and civil liberties. Prior to Palantir, Mr. Hood pursued a global multidimensional career as an international lawyer, human rights lawyer, and national security official. He has unique first-hand experience navigating some of the most complex legal and political challenges of our time, including prominent international war crimes trials and prosecutions. As a former member of the British Intelligence Services, Mr. Hood served as liaison between the UK and US intelligence communities on the highest priority national security operations of the time.
Ken Bedingfield serves as our Chief Financial Officer . Mr. Bedingfield currently serves as the Chief Operating Officer & Chief Financial Officer of Epirus, an AI-enabled power management company focused on directed energy defense applications that has raised over $140.0 million in capital. Mr. Bedingfield has scaled Epirus’ operations across finance, manufacturing, supply chain, human resources, contracts and pricing, and investor relations, positioning the company for rapid growth across defense and commercial markets. Prior to Epirus, Mr. Bedingfield served as Corporate Vice President and Chief Financial Officer of Northrop Grumman for over 5 years, where he was responsible for all finance-related activities, including cost and schedule management, contracts, pricing and estimating, supply chain, investor relations, and investments and the pension trust, overseeing over $50.0 billion in assets. During his tenure as Chief Financial Officer, Mr. Bedingfield helped lead several transformative initiatives that drove the company’s market capitalization expansion from less than $30.0 billion to over $60.0 billion. Among other successes, Mr. Bedingfield helped secure the B-21 Raider contract, strategically positioned the company for the GBSD program, oversaw the $8.0 billion acquisition of Orbital ATK, and issued over $10.0 billion of public debt. Prior to his role as Corporate Vice President and Chief Financial Officer, Mr. Bedingfield served as Chief Financial Officer of Northrop Grumman’s Aerospace Systems Sector. Prior to that role, Mr. Bedingfield served as Corporate Controller and Chief Accounting Officer of Northrop Grumman Corporation. Before joining Northrop Grumman, Mr. Bedingfield was a partner at KPMG LLP, where he ran the firm’s U.S. Aerospace & Defense audit practice. He joined KPMG after graduating from the University of Maryland in 1994.
Josh Lobel serves as the Chairman of our board of directors . Mr. Lobel is a Founding Partner at Red Cell and an accomplished investor and board member, with significant specialization in defense and health care. Mr. Lobel is the Chairman of Focus RoQ Holdings, a family office holding company specializing in aerospace, mobility, defense and health care. Mr. Lobel also Co-founded Archer Capital Management, a multi-asset class alternatives firm that he ran for 15 years, and is the CEO of Centerline Capital Management. His investing career spans significant investment in technology, media, telecommunications, transportation, aerospace and special purpose acquisition companies. He was also an early team member at Redwood Capital Management and held positions in the private equity and mergers and acquisitions groups at Morgan Stanley & Co. He is an early investor in and serves on the board of directors of Red 6 Aerospace and Sky Harbour, LLC, and is an investor in and adviser to AirMap. Mr. Lobel serves on the board of directors of the post-restructured Akorn Pharmaceuticals, the CIA Officers Memorial Foundation, where he serves as a member of the investment committee, and Cedars Sinai Medical System, where he serves as Chair of the Investment Committee. Mr. Lobel graduated from the University of California at Los Angeles and The Wharton School, University of Pennsylvania.
Grant Verstandig is a member of our board of directors . Mr. Verstandig is a Founding Partner at Red Cell and an accomplished healthcare and defense technology entrepreneur, investor, and technology advisor. Mr. Verstandig founded Rally Health, a consumer-centric digital health company acquired by UnitedHealth Group, and co-founded Epirus, an AI-enabled power management company focused on directed energy defense applications that has raised over $140.0 million in capital. Mr. Verstandig remains engaged with both companies, serving as Chief Digital Officer of UnitedHealth Group where he leads digital transformation across the enterprise and as Executive Chairman of Epirus where he spearheads growth strategy and supports a field-leading executive and technical team. With over a decade of experience solving some of the most complex technology challenges in healthcare and defense, Mr. Verstandig has developed keen insights regarding mission-critical enabling technologies and their use cases. Applying these insights as an investor and business-builder, Mr. Verstandig has backed numerous technology-led companies from their earliest stages through their successful transition into the public markets, including NexImmune (NASDAQ: NEXI), where he serves on the board of directors. A respected technologist as well as practitioner, Mr. Verstandig advises several public and civic institutions, including the National Security Agency where he serves as senior advisor on advanced analytics, technology, and artificial intelligence.